← Back to search

Protein Structures and Oligomeric States

Enter a protein name, UniProt accession or PDB ID. Name searches ask you to confirm the protein identity before related structures are queried.

Current Protein Identity：P28065 New Search
7PDB entries
7Biological assembly
14chain/assembly records
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
6AVO Cryo-EM structure of human immunoproteasome with a novel noncompetitive inhibitor that selectively inhibits activated lymphocytes Deposited 2017-09-04 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain A 21–219（199 aa）
Chain F 21–219（199 aa）
Not recorded BZ7 N~1~-{2-[([1,1'-biphenyl]-3-carbonyl)amino]ethyl}-N~4~-tert-butyl-N~2~-(3-phenylpropanoyl)-L-aspartamide × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.80 Å
6E5B Human Immunoproteasome 20S particle in complex with compound 1 Deposited 2018-07-19 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain N 1–219（219 aa）
Chain b 1–219（219 aa）
Not recorded SCN THIOCYANATE ION × 3 NA SODIUM ION × 12 HUJ [(1R)-3-methyl-1-[[1-[2-[(2,3,4-trimethoxyphenyl)carbonylamino]ethyl]-1,2,3-triazol-4-yl]carbonylamino]butyl]-tris(oxidanyl)boron × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；39% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.2M sodium thiocyanate
Resolution 2.77 Å R-free 0.291
7AWE HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid Deposited 2020-11-06 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain H 21–219（199 aa）
Chain V 21–219（199 aa）
Not recorded NA SODIUM ION × 13 SCN THIOCYANATE ION × 11 S5K [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；42 % MPD, 0.20 M NaSCN
Resolution 2.29 Å R-free 0.214
7B12 HUMAN IMMUNOPROTEASOME 20S PARTICLE IN COMPLEX WITH [2-(3-ethylphenyl)-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]ethyl]boronic acid Deposited 2020-11-23 Assembly 1 Protein heterocomplex Heteromer；Protein × 28 PDB declaration: 28-mer（28） Consistent with protein count
Chain H 21–219（199 aa）
Chain V 21–219（199 aa）
Not recorded SO4 SULFATE ION × 5 NA SODIUM ION × 6 SKN ((R)-2-(3-ethylphenyl)-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)ethyl)boronic acid × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；42 % MPD, 0.20 M NaSCN,
Resolution 2.43 Å R-free 0.225
9FRW Yeast 20S proteasome with human beta1i (1-51) Deposited 2024-06-19 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain N 21–65（45 aa）
Chain b 21–65（45 aa）
Mutation：Sequence 1-53 from human beta1i Mutation：Sequence 1-53 from human beta1i CL CHLORIDE ION × 7 MG MAGNESIUM ION × 9 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.85 Å R-free 0.227
9FST Yeast 20S proteasome with human beta1i (1-51) in complex with epoxyketone inhibitor LU-001i Deposited 2024-06-21 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain N 22–66（45 aa）
Chain b 22–66（45 aa）
Not recorded CL CHLORIDE ION × 4 MG MAGNESIUM ION × 8 A1IF8 azanylidene-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-2-cyclohexyl-1-[(2R,3S,6R,7S)-3-methanoyl-2,6-dimethyl-6,7-bis(oxidanyl)-1,4-oxazepan-7-yl]ethyl]amino]-1-oxidanylidene-hexan-2-yl]carbamoyl]-4,4-bis(fluoranyl)pyrrolidin-1-yl]-1-oxidanylidene-propan-2-yl]amino]-2-oxidanylidene-ethyl]imino-azanium × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 4 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.75 Å R-free 0.245
9FSU Yeast 20S proteasome with human beta1i (1-51) in complex with epoxyketone inhibitor 16 Deposited 2024-06-21 Assembly 1 Insufficient information Heteromer；Protein × 28 PDB declaration: 28-meric（28） Consistent with protein count
Chain N 21–65（45 aa）
Chain b 21–65（45 aa）
Not recorded MG MAGNESIUM ION × 9 CL CHLORIDE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 3 SO4 SULFATE ION × 4 A1IFL (2S)-N-[(2S)-1-[[(1S)-2-cyclohexyl-1-[(2R,3S,6R,7S)-3-methanoyl-2,6-dimethyl-6,7-bis(oxidanyl)-1,4-oxazepan-7-yl]ethyl]amino]-3-(4-methoxyphenyl)-1-oxidanylidene-propan-2-yl]-2-(2-morpholin-4-ylethanoylamino)-4-oxidanyl-butanamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；20 mM MgAC2, 13% MPD, 0.1 M MES
Resolution 2.75 Å R-free 0.245

This page presents structural evidence recorded in PDB/mmCIF.“No recorded non-water small molecule” does not prove that the experimental sample was ligand-free; experimental conditions belong to the PDB experiment, while ligands and copy counts are shown for each biological assembly.